Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Krina Patel

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
The Lancet. Haematology|March 27, 2019
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trialQaiser Bashir, Peter F Thall, Denái R Milton, et al.
Transplantation and Cellular Therapy|June 4, 2024
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World ExperienceJack Khouri, Danai Dima, Hong Li, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 28, 2019
Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched AnalysisAnkur Varma, Dawen Sui, Denái R Milton, et al.
Blood Advances|October 19, 2023
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapyLauren C Peres, Laura B Oswald, Christen M Dillard, et al.
Blood|August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analysesSikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2024
Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401David J Chung, Nina Shah, Juan Wu, et al.
Blood Cancer Journal|March 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy ConsortiumAndrew J Portuguese, James A Davis, Shahzad Raza, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
The Lancet. Haematology|March 27, 2019
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trialQaiser Bashir, Peter F Thall, Denái R Milton, et al.
Transplantation and Cellular Therapy|June 4, 2024
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World ExperienceJack Khouri, Danai Dima, Hong Li, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 28, 2019
Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched AnalysisAnkur Varma, Dawen Sui, Denái R Milton, et al.
Blood Advances|October 19, 2023
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapyLauren C Peres, Laura B Oswald, Christen M Dillard, et al.
Blood|August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analysesSikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2024
Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401David J Chung, Nina Shah, Juan Wu, et al.
Blood Cancer Journal|March 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy ConsortiumAndrew J Portuguese, James A Davis, Shahzad Raza, et al.
Pageof 8